Many Americans Are Using GLP-1 Drugs Without Medical Reason, New Report Suggests

A new report suggests that a significant number of Americans are using GLP-1 medications without a clear medical indication for their use Many Americans Use GLP-1 Drugs Without a Medical Reason, Study Shows (Google News, Tue, 22 Sep 2026). This news raises questions about how these powerful medications are being prescribed and used outside of their approved guidelines.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are a class of medications originally developed for type 2 diabetes. More recently, some GLP-1s have received FDA approval for chronic weight management. For example, the FDA-approved label for Wegovy (semaglutide) indicates its use for adults and pediatric patients aged 12 and older with obesity, or adults with overweight who also have at least one weight-related comorbid condition FDA / openFDA WEGOVY Label. It's also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, according to the FDA FDA / openFDA WEGOVY Label.

What Counts as a "Medical Reason"?

When we talk about a "medical reason" for GLP-1 drugs for weight management, we're generally referring to the conditions outlined in the FDA's approved indications. This typically means having obesity (a BMI of 30 kg/m² or greater) or being overweight (a BMI of 27 kg/m² or greater) with an associated health condition like high blood pressure, type 2 diabetes, or high cholesterol. These guidelines are in place because these medications are potent and carry potential side effects.

Why Does This Matter?

Using GLP-1 medications without an approved medical indication can carry several risks. The FDA label for Wegovy, for instance, lists common adverse reactions such as nausea, diarrhea, vomiting, constipation, and abdominal pain FDA / openFDA WEGOVY Label. More serious warnings include the risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, and acute kidney injury FDA / openFDA WEGOVY Label. These are significant considerations that should always be weighed by a healthcare professional based on your individual health profile.

Beyond the individual health risks, widespread use outside of approved indications could also impact the supply for those who meet the medical criteria and genuinely need these medications. This can lead to shortages, making it harder for people managing chronic conditions to access their prescribed treatments.

The Bigger Picture of Weight Management

It's understandable why these medications are so appealing; managing weight can be incredibly challenging. According to MedlinePlus, over 70% of adults in the United States are overweight or have obesity, and maintaining a healthy weight significantly lowers the risk for conditions like type 2 diabetes, heart disease, and certain cancers MedlinePlus (NIH) Weight Control. However, these medications are designed to be part of a comprehensive plan that includes a reduced-calorie diet and increased physical activity, not a standalone solution FDA / openFDA WEGOVY Label.

What this means for you

• Understand the indications: GLP-1 medications like Wegovy are FDA-approved for specific conditions related to obesity, overweight with comorbidities, and cardiovascular risk reduction.
• Discuss with your prescriber: If you're considering a GLP-1 medication, have an open conversation with your doctor about whether it's medically appropriate for your situation.
• Be aware of risks: All medications carry risks and side effects. Ensure you understand these thoroughly before starting any new treatment.

Not medical advice. Talk to your prescriber about your situation.